At Enrollment | Total Group, n = 768 | Patients Who Increased Total No. ACR Criteria in 1st 5 yrs, n = 454 | Patients Who Did Not Increase Total No. ACR Criteria in 1st 5 yrs, n = 314 | p |
---|---|---|---|---|
Female | 681 (88.7) | 412 (90.8) | 269 (85.7) | 0.03 |
Marital status (married/common law) | 349 (45.4) | 203 (44.7) | 146 (46.5) | 0.66 |
Ethnicity | ||||
Asian | 119 (15.5) | 69 (15.2) | 50 (15.9) | |
Black | 110 (14.3) | 69 (15.2) | 41 (13.1) | |
White | 387 (50.4) | 243 (53.5) | 144 (45.9) | 0.04* |
Hispanic | 128 (16.7) | 57 (12.6) | 71 (22.6) | |
Other | 24 (2.1) | 16 (3.5) | 8 (2.6) | |
Education > high school | 453 (59.2) | 272 (60.0) | 181 (58.0) | 0.57 |
SLEDAI-2K, mean ± SD | 5.6 ± 5.6 | 5.63 ± 5.62 | 5.50 ± 5.46 | 0.76 |
Age, yrs, mean ± SD | 35.0 ± 13.3 | 34.2 ± 13.0 | 36.1 ± 13.7 | 0.05 |
Disease duration, mos | 5.4 ± 4.1 | 5.2 ± 4.0 | 5.8 ± 4.3 | 0.07 |
Taking steroids at enrollment | 531 (69.1) | 306 (67.4) | 225 (71.7) | 0.21 |
Taking antimalarials at enrollment | 486 (63.3) | 282 (62.1) | 204 (65.2) | 0.39 |
Taking immunosuppressives at enrollment | 308 (40.1) | 171 (37.7) | 137 (43.6) | 0.1 |
Malar rash | 276 (35.9) | 162 (35.7) | 114 (36.3) | 0.86 |
Discoid rash | 83 (10.8) | 50 (11.0) | 33 (10.5) | 0.83 |
Oral ulcers | 294 (38.3) | 172 (37.9) | 122 (38.9) | 0.77 |
Serositis | 217 (28.3) | 128 (28.2) | 89 (28.3) | 0.96 |
Arthritis | 583 (75.9) | 330 (72.7) | 253 (80.6) | 0.01 |
Photosensitivity | 276 (35.9) | 176 (38.8) | 100 (31.9) | 0.05 |
Renal disease | 236 (30.7) | 123 (27.1) | 113 (36.0) | 0.009 |
Neurological disorder | 47 (6.1) | 32 (7.1) | 15 (4.8) | 0.2 |
Hematological disorder | 513 (66.8) | 269 (59.3) | 244 (77.7) | < 0.0001 |
Immunological disorder | 610 (79.4) | 353 (77.8) | 257 (81.9) | 0.17 |
Antinuclear antibodies | 734 (95.6) | 434 (95.6) | 300 (95.5) | 0.97 |
Total no. ACR criteria | 5.04 ± 1.13 | 4.91 ± 1.03 | 5.22 ± 1.25 | 0.0003 |
↵* Comparing whites to all other ethnicities combined. SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index 2000.